Stevens Capital Management LP Makes New $217,000 Investment in Illumina, Inc. (NASDAQ:ILMN)

Stevens Capital Management LP acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the 4th quarter, HoldingsChannel reports. The fund acquired 1,556 shares of the life sciences company’s stock, valued at approximately $217,000.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Eukles Asset Management boosted its stake in shares of Illumina by 1.7% in the third quarter. Eukles Asset Management now owns 5,942 shares of the life sciences company’s stock valued at $816,000 after purchasing an additional 100 shares during the period. Clear Creek Financial Management LLC boosted its stake in shares of Illumina by 6.3% in the fourth quarter. Clear Creek Financial Management LLC now owns 1,695 shares of the life sciences company’s stock valued at $236,000 after purchasing an additional 100 shares during the period. Lido Advisors LLC boosted its stake in shares of Illumina by 6.1% in the third quarter. Lido Advisors LLC now owns 1,859 shares of the life sciences company’s stock valued at $255,000 after purchasing an additional 107 shares during the period. Quent Capital LLC boosted its stake in shares of Illumina by 45.2% in the fourth quarter. Quent Capital LLC now owns 363 shares of the life sciences company’s stock valued at $51,000 after purchasing an additional 113 shares during the period. Finally, Independent Advisor Alliance boosted its stake in shares of Illumina by 8.6% in the third quarter. Independent Advisor Alliance now owns 1,595 shares of the life sciences company’s stock valued at $219,000 after purchasing an additional 126 shares during the period. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO Jacob Thaysen bought 7,330 shares of the firm’s stock in a transaction on Thursday, February 22nd. The stock was bought at an average cost of $135.29 per share, for a total transaction of $991,675.70. Following the completion of the acquisition, the chief executive officer now directly owns 14,861 shares in the company, valued at approximately $2,010,544.69. The purchase was disclosed in a document filed with the SEC, which is available at this link. Insiders own 0.17% of the company’s stock.

Analyst Ratings Changes

ILMN has been the subject of several analyst reports. OTR Global restated a “mixed” rating on shares of Illumina in a research note on Wednesday, March 20th. TD Cowen cut shares of Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 price target on the stock. in a report on Thursday, January 4th. Barclays upped their price target on shares of Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a report on Wednesday, April 10th. Stephens reaffirmed an “overweight” rating and issued a $170.00 price target on shares of Illumina in a report on Wednesday, April 10th. Finally, HSBC cut shares of Illumina from a “buy” rating to a “hold” rating in a report on Tuesday, January 16th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $167.70.

Illumina Stock Up 1.0 %

Shares of NASDAQ:ILMN traded up $1.23 on Friday, reaching $122.28. 829,310 shares of the company’s stock were exchanged, compared to its average volume of 1,718,479. Illumina, Inc. has a fifty-two week low of $89.00 and a fifty-two week high of $213.91. The business’s 50-day moving average is $131.94 and its two-hundred day moving average is $127.50. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.26.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, February 8th. The life sciences company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The business had revenue of $1.12 billion for the quarter, compared to analysts’ expectations of $1.09 billion. During the same quarter last year, the company earned $0.14 EPS. The company’s revenue for the quarter was up 3.6% compared to the same quarter last year. As a group, equities analysts predict that Illumina, Inc. will post 0.91 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.